Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

Investors were surely discovering drug discovery company AbCellera Biologics (NASDAQ: ABCL) as the trading week kicked off on Monday. On encouraging news in an important North American jurisdiction, those folks bid the biotech's stock up by almost 6% on the day. That was a far higher jump than the 0.4% increase of the benchmark S&P 500 index.

Moving forward with dermatitis treatment

Friday afternoon, AbCellera announced that it had received a no objection letter (NOL) from Health Canada, that country's healthcare regulatory agency, regarding one of its early-stage investigational drugs. The NOL covers the company's clinical trial application (CTA) for ABCL575, a treatment that targets moderate to severe atopic dermatitis (a chronic skin condition also known as atopic eczema).

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Image source: Getty Images.

Receipt of an NOL is an important step in advancing a clinical program for companies like AbCellera, hence the positive market reaction to the news.

AbCellera said in its press release revealing the NOL that it anticipates launching a phase 1 clinical study of ABCL575 in the third calendar quarter of this year. It will be administered by injection to trial participants.

One of very many

AbCellera is a busy company, boasting over 20 investigational programs that sprawl across a number of indications. To some degree, this latest news item is something of a drop in the bucket, particularly since AbCellera's native Canadian market is significantly smaller than that of the U.S.

Regardless, any good news coming from a regulator is a positive for a biotech, so investors were right to cheer Health Canada's move.

Where to invest $1,000 right now

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 979%* — a market-crushing outperformance compared to 171% for the S&P 500.

They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.

See the stocks »

*Stock Advisor returns as of June 2, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbCellera Biologics. The Motley Fool has a disclosure policy.